AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAY 14 - (NewsRx.com & NewsRx.net) -- Recent research in Germany suggests that humoral immune responses play a supportive role in the efficacy of amodiaquine treatment for malaria.
According to the study, "The relationship between the efficacy of amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria and preexisting antibodies against merozoite surface protein (MSP)-1, a blood-stage P. falciparum antigen, were investigated.
"The immunoglobulin G antibody response to different MSP-1 recombinant proteins was evaluated in plasma samples from Gabonese children with uncomplicated malaria who were treated with amodiaquine," wrote D. P. Mawilimboumba and colleagues, University of Tubingen.
"The prevalence of anti-MSP-1 antibodies was similar among patients with either parasitological and clinical cure after treatment (n = 102) or treatment failure (n = 51) by day 28 ( 83% in both groups).
"However, associations between antibody responses to K1 and MAD20 allelic families and therapeutic success were found (p
"This association was significant even when data were stratified by age, particularly for the K1 ...